Dr. Arlen directs outreach efforts on behalf of the Conrad Prebys Center for Chemical Genomics at Sanford Burnham Prebys Medical Discovery Institute. By providing access to SBP’s expertise, infrastructure, and resources dedicated to drug discovery, the Center helps its partners develop and move compounds to clinical assessment efficiently and cost-effectively. He also oversees outreach on behalf of the Florida Translational Research Program, a collaborative drug discovery initiative established by Sanford Burnham Prebys and the State of Florida.
Prior to joining SBP, Dr. Arlen was Chief Scientific Officer of Revolution Medicine, an early-stage medical informatics company he co-founded that provides personalized medicine solutions. In partnership with healthcare providers and payers, Revolution Medicine applies its proprietary technology and algorithms to analyze DNA information for clinical relevance and to determine optimal treatment plans for each individual patient.
Dr. Arlen’s career began at the Prostate Cancer Foundation, where he helped Michael Milken create the first nationwide organization of translational research scientists and clinicians dedicated to eradicating prostate cancer. Prior to founding Revolution Medicine, Dr. Arlen was a faculty member at the MD Anderson Cancer Center in Orlando, Florida. He directed the Early Stage Interventions Laboratory, which studied the relationship between cancer and the immune system, with specific areas of focus in cancer vaccines, tumor biomarkers, and immunodiagnostics.
Dr. Arlen earned a BS in Biology from Cornell University and PhD in Microbiology, Immunology, and Molecular Genetics from the University of California, Los Angeles. He holds a faculty appointment as Assistant Professor in the Burnett School of Biomedical Sciences at the University of Central Florida and is a member of the Board of Directors of BioFlorida, the state’s trade association for the life sciences industry.